We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-1.41%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.59B
AUM Growth
-$205M
(-7.3%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-4.06%
Top 10 Holdings %
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
45
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$42.8M |
| 2 |
AbbVie
ABBV
|
+$22.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$21.8M |
| 4 |
CELG
Celgene Corp
CELG
|
+$14.3M |
| 5 |
NVO
Novo Nordisk
NVO
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$25.1M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$24.3M |
| 3 |
AGN
Allergan plc
AGN
|
+$23.5M |
| 4 |
Gilead Sciences
GILD
|
+$21.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$16.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.75% |
| 2 | Real Estate | 2.87% |
| 3 | Financials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$163B
| $181M | 6.96% |
2,520,281
-280,850
| -10% | -$21.3M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $158M | 6.09% |
1,513,904
+126,379
| +9% | +$14.3M |
|
|
3
Amgen
AMGN
$209B
| $150M | 5.78% |
862,174
+241,900
| +39% | +$42.8M |
|
4
Biogen
BIIB
$30.7B
| $142M | 5.48% |
445,607
-43,997
| -9% | -$14.1M |
|
5
Johnson & Johnson
JNJ
$617B
| $103M | 3.97% |
736,132
-62,800
| -8% | -$8.75M |
|
6
Vertex Pharmaceuticals
VRTX
$122B
| $96.5M | 3.72% |
643,762
-87,361
| -12% | -$12.9M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
| $78.9M | 3.04% |
659,618
-91,287
| -12% | -$11.1M |
|
8
Merck
MRK
$321B
| $74.4M | 2.87% |
1,385,660
-158,353
| -10% | -$8.78M |
|
9
Viatris
VTRS
$20.7B
| $67.8M | 2.62% |
1,603,112
| – | – |
|
10
UnitedHealth
UNH
$383B
| $67.4M | 2.6% |
305,886
+30,060
| +11% | +$6.37M |
|
11
Incyte
INCY
$24.9B
| $65.7M | 2.53% |
693,275
| – | – |
|
12
Regeneron Pharmaceuticals
REGN
$77.4B
| $64.1M | 2.47% |
170,516
| – | – |
|
13
Illumina
ILMN
$31B
| $62.4M | 2.41% |
293,793
-31,765
| -10% | -$6.54M |
|
|
14
Abbott
ABT
$183B
| $45.6M | 1.76% |
798,619
-452,301
| -36% | -$25.1M |
|
15
BioMarin Pharmaceuticals
BMRN
$11.7B
| $43.7M | 1.68% |
489,745
-12,000
| -2% | -$1.04M |
|
16
Medtronic
MDT
$110B
| $40.9M | 1.58% |
506,026
-74,300
| -13% | -$5.95M |
|
17
Pfizer
PFE
$142B
| $35.3M | 1.36% |
1,027,742
+173,910
| +20% | +$5.93M |
|
18
Humana
HUM
$44B
| $34.4M | 1.33% |
138,556
+13,775
| +11% | +$3.4M |
|
|
AGN
19
DELISTED
Allergan plc
AGN
| $34.1M | 1.31% |
208,180
-130,799
| -39% | -$23.5M |
|
|
20
AbbVie
ABBV
$455B
| $33.5M | 1.29% |
346,313
+241,800
| +231% | +$22.8M |
|
21
Eli Lilly
LLY
$1.03T
| $32.4M | 1.25% |
383,099
-5,001
| -1% | -$426K |
|
22
Novartis
NVS
$301B
| $32.1M | 1.24% |
426,180
-18,727
| -4% | -$1.41M |
|
|
SHPG
23
DELISTED
Shire pic
SHPG
| $31.3M | 1.21% |
201,739
-50,374
| -20% | -$7.47M |
|
24
Teva Pharmaceuticals
TEVA
$41.2B
| $30M | 1.16% |
1,583,108
-173,450
| -10% | -$2.61M |
|
25
CVS Health
CVS
$134B
| $26.6M | 1.02% |
366,521
-45,370
| -11% | -$3.3M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q4 2017 Portfolio in Review
As of Q4 2017, Tekla Capital Management held 169 positions worth $2.59B, down 7.3% from $2.8B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Tekla Capital Management withdrew a net $105M in Q4 2017, closing 8 positions and reducing 45 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $7.15M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.
Against the trend, Tekla Capital Management opened a new position in Bristol-Myers Squibb worth $21.4M.
- Tekla Capital Management's largest Q4 2017 buy was Bristol-Myers Squibb: 349,121 shares worth $21.4M.
- Tekla Capital Management added most to Amgen in Q4 2017, an estimated $42.8M increase.
- Tekla Capital Management's biggest Q4 2017 reduction was Abbott, cutting an estimated $25.1M.
- Tekla Capital Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2017, selling an estimated $7.15M.
- Tekla Capital Management's ten largest holdings make up 43% of its $2.59B portfolio in Q4 2017.
- Tekla Capital Management opened 17 new positions and closed 8 in Q4 2017.
- Tekla Capital Management's portfolio value fell 7.3% quarter-over-quarter to $2.59B.
Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.